NCT01640665View on ClinicalTrials.gov

Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Metastatic Breast CancerGastrointestinal Tumors
Interventions
DRUG

Sorafenib

One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.

DRUG

Capecitabine

Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.

Trial Locations (1)

06519

Yale Cancer Center, New Haven

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Yale University

OTHER